Dr. Mohammad Chafic El-Hajjar, MD

Dr. El-Hajjar practices at Albany Medical Center in Albany, New York, part of Albany Med Health System.

Dr. El-Hajjar's NPI, 1073783577, was assigned on March 11, 2008. Dr. El-Hajjar holds Indiana license 01063037A.

Dr. El-Hajjar's primary practice is Albany Medical Center, at 43 New Scotland Avenue, Mail Code 34, Albany, NY 12208 in Albany County. The practice phone is (518) 262-2400.

Dr. El-Hajjar's primary practice is Albany Medical Center in Albany, New York, part of Albany Med Health System. Dr. El-Hajjar is also affiliated with Samaritan Hospital. The medical group on file is Albany Med EmUrgentCare. Dmand AI also links Dr. El-Hajjar to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. El-Hajjar practices, 7 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. El-Hajjar's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. El-Hajjar is board certified in cardiovascular disease by the American Board of Internal Medicine. Dmand AI has Dr. El-Hajjar's licenses on file in 2 states: Indiana and New York.

CMS data shows 698 Medicare services from Dr. El-Hajjar across 16 procedure codes in 2024, for 322 Medicare patients. Medicare paid $82,684 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 322 Medicare patients who saw Dr. El-Hajjar in 2024. The largest group is 75 to 84, with 113 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 21% are also on Medicaid. Their average risk score is 1.89, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. El-Hajjar's median patient age at 66, with 44% women.

In 2024, Dr. El-Hajjar wrote 948 Medicare Part D claims for 124 patients. 86% of them were for generic drugs. CMS names the drug for 801 of them, across 23 drugs with 11 or more claims each, at $85,244 in total drug cost. In 2023, CMS named 715 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. El-Hajjar for performance year 2024, reported as part of a group. Dr. El-Hajjar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 33 procedures of coronary angioplasty and stenting by Dr. El-Hajjar, more than 69% of the clinicians it reports for that procedure.

Dmand AI links 13 papers to Dr. El-Hajjar, published from 2015 to 2023. 2015 was the busiest year, with 2. The most frequent topics are Aortic Valve Stenosis, Coronary Artery Disease and Electrocardiography. Dr. El-Hajjar has published most often in BMJ Case Rep. Dr. El-Hajjar's most frequent co-authors are Joshua Schulman-Marcus, MD, Robert Avram and Malcolm R. Bell, MD.

Dmand AI links Dr. El-Hajjar to 4 clinical trials. 3 are still active or recruiting. Conditions studied include Heart Valve Diseases, Mitral Valve Insufficiency and Foramen Ovale, Patent. Abbott Medical Devices sponsors the most, 3.

CMS Open Payments shows 442 general payments to Dr. El-Hajjar from 37 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 53% of the total. Boston Scientific Corporation paid the most, $32,443.